Xifaxan (rifaximin) is now approved for preventing hepatic encephalopathy due to chronic liver disease

Prescriber Insights: APRN includes:

• Cutting-edge advice about new medications and how they fit into practice
• Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
• Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote